Wezlana (ustekinumab-auub) — Medica

Initial criteria

• age ≥ 6 years
• patient has tried at least one traditional systemic agent for psoriasis for at least 3 months unless intolerant OR has a contraindication to methotrexate
• medication is prescribed by or in consultation with a dermatologist

Reauthorization criteria

• patient has been established on the requested drug for at least 3 months
• patient experienced a beneficial clinical response defined as improvement from baseline in estimated body surface area, erythema, induration/thickness, and/or scale of areas affected by psoriasis
• improvement in at least one symptom such as decreased pain, itching, and/or burning

Approval duration

initial: 3 months; reauth: 1 year